NCT00385593

Symbicort Single Inhaler Therapy vs Conventional Best Practice for the Treatment of Persistent Asthma in Adults

A Comparison of Symbicort Single Inhaler Therapy (Symbicort Turbuhaler 160/4.5 Micrograms, 1 Inhalation b.i.d. Plus as Needed) and Conventional Best Practice for the Treatment of Persistent Asthma in Adults - a 26-week, Randomised, Open-label, Parallel-group, Multicentre Study. Study SPAIN

• Status: Terminated
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 654 (actual)
• Sponsor: AstraZeneca · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study is intended to extend the knowledge of Symbicort Single Inhaler Therapy into a more general setting in order to assess the real-life impact of introducing this new treatment concept. The study will compare the Symbicort Single Inhaler Therapy concept with a conventional stepwise treatment regimen according to the investigator's judgement in patients who present with symptoms on inhaled glucocorticosteroids (GCS) treatment or who require and are already on treatment with a combination of inhaled and long-acting B2 agonists (LABA).

Conditions

• Asthma, Bronchial

Interventions

Type	Name	Description
DRUG	Symbicort (budesonide/formoterol) Turbuhaler
DRUG	Conventional treatment

Timeline

• Start date: 2006-09-01
• Completion: 2008-10-01
• First posted: 2006-10-09
• Last updated: 2010-12-16
• Results posted: 2009-11-17

Locations

52 sites across 1 country: Spain